
FACSIMILE MESSAGE - PLEASE DELIVER PROMPTLY

October 7, 2004

TO: Examiner Maryam Monshipouri
Group 1652
571-272-0932

RECEIVED
CENTRAL FAX CENTER

OCT 07 2004

FROM Justin D. Karjala
Celera Genomics Corp.
(240) 453-3812

FAX NO: (703) 872-9306

OF PAGES (incl. cover): 6

Re: U.S. Serial No. 10/820,230, filed April 8, 2004
Entitled "ISOLATED HUMAN KINASE PROTEINS, NUCLEIC ACID
MOLECULES ENCODING HUMAN KINASE PROTEINS, AND USES
THEREOF"
Atty. Docket No.: CL001178-DIVIII

A Preliminary Amendment (Restriction Election) in the above-identified application follows. No fee is due for this submission.

The information contained within this facsimile message is intended only for the personal and confidential use of the designated recipient named above. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution or copying of this message is strictly prohibited. If you have received this communication in error, please notify the sender immediately by telephone and return the original message to us by mail. Thank you for your cooperation.

RECEIVED
CENTRAL FAX CENTER

OCT 07 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Chunhua YAN et al.

Art Unit: 1652

Serial No.: 10/820,230

Examiner: M. Monshipouri

Filed: April 8, 2004

Atty. Docket: CL001178-DIVIII

For: ISOLATED HUMAN KINASE PROTEINS,
NUCLEIC ACID MOLECULES ENCODING
HUMAN KINASE PROTEINS, AND USES
THEREOF

PRELIMINARY AMENDMENT

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

By Facsimile

Sir:

This is in response to an Office Action mailed on September 7, 2004 from Examiner Monshipouri in which a restriction requirement was issued for the above-referenced application.

By way of response, Applicants hereby elect claim group II, claims 3 and 12, directed to antibodies and methods of detecting polypeptides using antibodies, etc., for examination and have canceled claims corresponding to the non-elected groups I and III-VIII.

Please amend the application as follows: